Skip to content

Study · Not a test of the peptide alone · 2019

1 result

[A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology].

Belova LA, Mashin VV, Dudikov EM, Belov DV, Krupennikov AA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2019Cited by 5 (Europe PMC)

PMID30874524 (opens in a new tab)DOI10.17116/jnevro201911902135 (opens in a new tab)PepBankPUB-30874524
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

  1. 01HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome

    In patients with chronic cerebrovascular pathology, cortexin plus citicoline was reported effective for vascular cognitive disorders.

    In plain wordsIn patients with chronic cerebrovascular disease, cortexin plus citicoline was reported effective for cognitive disorders.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseCognitive function
    Study

    n = 309

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Complex therapy with cortexin and recognan (citicoline) showed high efficacy in the treatment of vascular cognitive disorders.
    3 context sentences
    Summary · context
    Presented is an analysis of results of the multicenter observation program to assess the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in patients with chronic cerebrovascular pathology.
    Summary · context
    Three hundred and nine patients with chronic cerebrovascular pathology, including 134 (43.4%) men and 175 (56.6%) women, aged from 30 to 80, average age 63.4±9.4 years, with confirmed cognitive deficit were examined.
    Summary · context
    All patients received cortexin and recognan (citicoline) ('Geropharm', Russia) at doses 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.